Abstract
In the past few years, some major advancements in liposome technology have induced the rapid development of new pharmaceutical liposomal applications. For the purpose of optimizing the delivery of factors for maximum efficacy, novel methods have been proposed to increase the permeation rate of drugs temporarily and deliver the desired target compound in a time-regulated and locally restricted manner to the target site.
Lipid-based nanoparticles (LNPs) are promising delivery vectors in the treatment of cancer, inflammation, and infections and are already used in clinical practice. Numerous strategies based on LNPs are being developed to carry drugs into specific target sites. The common purpose for all of these LNP-based platforms is to improve the payload’s pharmacokinetics, biodistribution, stability, and therapeutic benefits and also to reduce adverse effects to a minimum. In addition, the delivery system must be biocompatible and nontoxic and should avoid undesirable interactions with the immune system. The rapid advancement in nanotechnology has allowed the emergence of theranostic NPs, which have shown advantages of diagnosis and drug delivery as well as targeting the biomarkers of the disease at the molecular level.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Janib SM, Moses AS, Andrew MacKay J. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;62(11):1052–63.
Ma X, Zhao Y, Liang X-J. Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc Chem Res. 2011;44(10):1114–22.
Chen F, Ehlerding EB, Cai W. Theranostic nanoparticles. J Nucl Med. 2014;55(12):1919–22.
Sharma G, Sharma AR, Nam JS et al. Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes. J Nanobiotechnol, 2015;13:74.
Kang H, Mintri S, Menon AV, Lee HY, Choi HS, Kim J. Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles. Nanoscale. 2015;7:18848–62.
Ryu JH, Lee S, Son S, Kim SH, Leary JF, Choi K, Kwon IC. Theranostic nanoparticles for future personalized medicine. J Control Release. 2014;190:477–84.
Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71:161–72.
Landesman-Milo D, Peer D. Altering the immune response with lipid-based nanoparticles. J Control Release. 2012;161(2):600–8.
Fatemah B, Khaled G, Sebastien T. Nanotechnology in insulin delivery for management of diabetes, 2019;7:2.
**ng H, Zheng X, Ren Q, et al. Computed tomography imaging-guided radiotherapy by targeting upconversion nanocubes with significant imaging and radiosensitization enhancements. Sci Rep. 2013;3:1751.
Chen Z, Penet MF, Nimmagadda S, et al. PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano. 2012;6:7752–62.
Muthu MS, Leong DT, Mei L, Feng S-S. Nanotheranostics: application and further development of nanomedicine strategies for advanced theranostics. Theranostics. 2014;4:660–77.
Lee GY, Qian WP, Wang L, et al. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano. 2013;7:2078–89.
Bhuniya S, Maiti S, Kim EJ. An activatable theranostic for targeted cancer therapy and imaging. Angew Chem Int Ed Engl. 2014;53:4469–74.
Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev. 2012;64:1394–416.
Park J-H, Cho H-J, Yoon HY, Yoon I-S, Ko S-H, Shim J-S, Cho J-H, Park JH, Kim K, Kwon IC, Kim D-D. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. J Control Release. 2014;174:98–108.
John AE, Luckett JC, Tatler AL, Awais RO, Desai A, Habgood A, Ludbrook S, Blanchard AD, Perkins AC, Jenkins RG, Marshall JF. Preclinical SPECT/CT imaging of αvβ6 integrins for molecular stratification of idiopathic pulmonary fibrosis. J Nucl Med. 2013;54:2146–52.
Yang S, Chen Y, Ahmadie R, Ho EA. Advancements in the field of intravaginal siRNA delivery. J Control Release. 2013;167:29–39.
Kim K, Kim JH, Park H, Kim Y-S, Park K, Nam H, Lee S, Park JH, Park R-W, Kim I-S, Choi K, Kim SY, Park K, Kwon IC. Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release. 2010;146:219–27.
Lee J, Huh Y, Jun Y, Seo J, Jang J, Song H, Kim S, Cho E, Yoon H, Suh J. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 2006;13(1):95–9.
Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev. 2009;109:259–302.
Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, Wu X, Mao H. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 2010;70(15):6303–12.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pandey, P., Patel, J., Kumar, S., Pathak, Y. (2022). Pharmacokinetics and Pharmacodynamics of Liposomal Nanoparticles. In: Patel, J.K., Pathak, Y.V. (eds) Pharmacokinetics and Pharmacodynamics of Nanoparticulate Drug Delivery Systems . Springer, Cham. https://doi.org/10.1007/978-3-030-83395-4_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-83395-4_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-83394-7
Online ISBN: 978-3-030-83395-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)